Article Versions Notes

Ecke TH, Huang-Tiel H-J, Golka K, Selinski S, Geis BC, Koswig S, Bathe K, Hallmann S, Gerullis H. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. International Journal of Molecular Sciences. 2016; 17(11):1879. https://doi.org/10.3390/ijms17111879

Ecke, Thorsten H., Hui-Juan Huang-Tiel, Klaus Golka, Silvia Selinski, Berit Christine Geis, Stephan Koswig, Katrin Bathe, Steffen Hallmann, and Holger Gerullis. 2016. "Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer" International Journal of Molecular Sciences 17, no. 11: 1879. https://doi.org/10.3390/ijms17111879

Ecke, T. H., Huang-Tiel, H.-J., Golka, K., Selinski, S., Geis, B. C., Koswig, S., Bathe, K., Hallmann, S., & Gerullis, H. (2016). Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. International Journal of Molecular Sciences, 17(11), 1879. https://doi.org/10.3390/ijms17111879